Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

In addition to basic blocking and tackling, compliance officers often have the thankless job of performing the annual review ...

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...

Credit: Volha_R/Shutterstock. Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta (quizartinib) in adults with newly diagnosed, ...

SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3- expressing hematologic malignancies, including AML, while sparing ... in a bone marrow sample by the most sensitive ...

For this study, researchers analyzed data from the 2020-2021 National Inpatient Sample. The cohort included 28,028 patients with AML, 336 of whom were admitted to the hospital for COVID-19 (1.2% ...

The trial focuses on aggressive haematological cancers, including acute myeloid leukaemia (AML) and MDS. These malignancies are known for high levels of treatment resistance and poor clinical outcomes ...

The number of neutrons changes over time during radioactive decay, making the ratio of different isotopes in a sample a good way to measure how old that sample is. Related: Moon Surprisingly ...